深城交(301091.SZ):全資子公司獲得高新技術企業認定
格隆匯12月6日丨深城交(301091.SZ)公佈,公司之全資子公司北京深研於近日收到由北京市科學技術委員會、北京市財政局、國家税務總局北京市税務局聯合頒發的《高新技術企業證書》,根據《中華人民共和國企業所得税法》及國家對高新技術企業的相關税收規定,北京深研自取得高新技術企業資格證書年度起,可連續三年申報享受15%企業所得税優惠税率及其它相關税收優惠政策。
該證書的取得,是對北京深研在技術研發和自主創新方面作出的努力所給予的肯定和鼓勵,將對公司未來的經營業績產生積極影響,對公司的經營發展也有着積極的推動作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.